In the past few years, there have been several debates regarding the de-escalation or discontinuation of disease-modifying therapies (DMTs) in various immunemediated disorders, such as multiple sclerosis and rheumatoid arthritis, when in remission. 1, 2 The reason is due to the fact that many patients remain in quiescent condition and for them to be on lifelong treatment would entail potential long-term side effects.
Neuromyelitis optica spectrum disorders (NMOSD), an autoimmune disease mediated mainly by antiaquaporin-4 channelopathy antibodies (AQP4-IgG), are characterized by acute episodes of diverse clinical presentations such as transverse myelitis, optic neuritis, brainstem, and other cerebral manifestations. This disorder requires immunosuppressant treatment to prevent further disease activity. 3 However, there is no consensus about the duration of these immunosuppressive therapies.
In real practice, many patients will request to have the treatment stopped, particularly those who have not experienced attacks or do not have evidence of disease activity for long periods of time. In addition, patients who had a childhood onset will need to have a balance between effectiveness of the treatment and the potential long-term side effects.
While several experts have suggested lifelong therapy for NMOSD patients, given the often devastating nature of the relapses, others have suggested to tailor the length of immunosuppression according to the severity of attacks and disability. However, there is no level (A) evidence to guide physicians in this decision. Herewith, we will highlight some points that would help define the potential cut-off of treatment length in selective cases.
A large retrospective cohort study demonstrated that around one-fifth of NMOSD patients remained asymptomatic after their inaugural presentation, supporting the concept that NMOSD might be with monophasic course in around 20% of patients. 4, 5 Some experts would keep patients with monophasic course on DMTs for at least 5 years, 6 before discontinuing it. This would suggest that long-term therapy is not needed in patients who did not disseminate in time either clinically or radiologically.
The decision to discontinue DMTs can also be based on prognostic features in the first 2 years of the disease. Worse prognosis can be expected based on number of relapses, severity of the first attack, older age at disease onset, and (perhaps) an association with other autoimmune disorders including autoantibody status. 5 Relapses occur within the first year following an initial event in 60% of patients and within 3 years in 90%, leading to rapid development of disability due to blindness and paraplegia within 5 years. 7 Furthermore, the concept of early and aggressive induction therapy instead of escalation therapy may also improve the underlying immune disturbance, leading to drug-free prolonged remission and reverse antibody seropositivity. Weinfurtner et al. 8 presented a case series of four NMO patients who remained in remission for 4.5-10.5 years, even if they were off treatment for 3-9 years. Patients had good clinical response despite normal B-lymphocyte levels, and while two patients remained seropositive for aquaporin-4 antibodies, the others two converted to negative status. Although there is a concern that positive AQP4-IgG NMOSD patients might carry a worse prognosis, it has been reported that seronegative and seropositive NMO patients were similar in terms of relapse rate, severity, and long-term outcomes. 9 In addition, few NMOSD patients might remain clinically stable for decades, without starting any treatment. 10 The main concern in discontinuing therapy is the risk of relapse, as a single NMO relapse can result in significant disability. However, it has been suggested 8 that stopping rituximab treatment after disease stabilization may be an option for some patients, thus avoiding the side effects and costs associated with long-term rituximab.
Disease-modifying therapies should be stopped in NMOSD patients in remission -Yes
It is crucial to identify those patients who have a realistic chance to taper medications. However, there is no consensus on the relapse rate decrease that would allow discontinuation of DMTs. I would suggest classifying patients into three groups: the "early remission" group, when remission was achieved within 5 years after baseline; the "intermediate remission" group, when remission was achieved between 5 and 10 years after baseline; and the "late remission" group, when remission was obtained after 10 years. Remission would be defined as sustained absence of clinical relapses or new lesions on imaging for the entire follow-up period.
Treatment cessation in stable patients should be optional and based on an unbiased discussion of the pros and cons. In the lack of scientific evidence, discontinuation of DMTs in patients with NMOSD is a difficult decision based on incomplete data as it is yet unknown whether this disease outcome is modifiable with current medications. De-escalation therapy would be an alternative in patients who have been stable on rituximab for several years, with a dosing interval of 12 months instead of 24 months doses, or with a switch to azathioprine or mycophenolate mofetil. Large prospective randomized trials in a larger population of patients are needed to provide guidelines on the optimal approach.
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The author(s) received no financial support for the research, authorship, and/or publication of this article. The possibility of an exit plan for discontinuing therapy is a frequently posed question in the clinic, but one of the least studied aspects of medical management. Clinical trials focus on the benefits of therapeutic intervention at the moment when disease is most active. In the case of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), clinical trial inclusion criteria routinely require evidence of a relapse or gadolinium-enhancing lesions within the past 1-2 years. Yet particularly for chronic inflammatory disorders, the propensity for new activity may wane over time, while the potential for adverse events on immunotherapy is thought to increase as patients age.
